Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2018; 10(3): 71-81
Published online Mar 15, 2018. doi: 10.4251/wjgo.v10.i3.71
Fusobacterium nucleatum and colorectal cancer: A review
Fu-Mei Shang, Hong-Li Liu
Fu-Mei Shang, Hong-Li Liu, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Supported by the National Natural Science Foundation of China, No. 81472707.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Hong-Li Liu, MD, PhD, Professor, Chief Physician, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China.
Telephone: +86-27-85871962 Fax: +86-27-65650733
Received: December 8, 2017
Peer-review started: December 8, 2017
First decision: December 22, 2017
Revised: January 9, 2018
Accepted: March 6, 2018
Article in press: March 6, 2018
Published online: March 15, 2018
Core Tip

Core tip: Fusobacterium nucleatum (F. nucleatum) promotes the progress of colorectal adenomas involving in multiple potential mechanisms. F. nucleatum positivity in colorectal cancer (CRC) is different in different research groups. Some potential biomarkers may be regarded as a criterion for judging CRC prognosis. Some chemoprevention and immunotherapy strategies on F. nucleatum-positive colorectal cancer need to be further explored in the future.